These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11256201)

  • 1. [Mouth opening in patients with systemic sclerosis: base analysis and during follow-up].
    Tanturri De Horatio C; Tirri E; Valletta R; Tirri G; Rengo S
    Minerva Stomatol; 2000 Sep; 49(9):409-13. PubMed ID: 11256201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
    Calguneri M; Apras S; Ozbalkan Z; Ertenli I; Kiraz S; Ozturk MA; Celik I
    Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of oral methotrexate in the treatment of systemic sclerosis.
    Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T
    Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients.
    Sulli A; Secchi ME; Pizzorni C; Cutolo M
    Ann Rheum Dis; 2008 Jun; 67(6):885-7. PubMed ID: 18037628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of reproductive history in systemic sclerosis.
    Bernatsky S; Hudson M; Pope J; Vinet E; Markland J; Robinson D; Jones N; Docherty P; Abu-Hakima M; Leclercq S; Dunne J; Smith D; Mathieu JP; Khalidi N; Sutton E; Baron M;
    Arthritis Rheum; 2008 Nov; 59(11):1661-4. PubMed ID: 18975360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Orofacial manifestations of systemic sclerosis: A study of 30 consecutive patients].
    Vincent C; Agard C; Barbarot S; N'guyen JM; Planchon B; Durant C; Pistorius MA; Dreno B; Ponge T; Stalder JF; Mercier JM; Hamidou M
    Rev Stomatol Chir Maxillofac; 2010 Jun; 111(3):128-34. PubMed ID: 20553704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of DMARDs in systemic sclerosis therapy.
    Blank N; Max R; Lorenz HM
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii42-4. PubMed ID: 16987834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
    Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transverse myelitis in systemic sclerosis.
    Torabi AM; Patel RK; Wolfe GI; Hughes CS; Mendelsohn DB; Trivedi JR
    Arch Neurol; 2004 Jan; 61(1):126-8. PubMed ID: 14732630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease.
    Kowal-Bielecka O; Distler O; Kowal K; Siergiejko Z; Chwiećko J; Sulik A; Gay RE; Łukaszyk AB; Gay S; Sierakowski S
    Arthritis Rheum; 2003 Jun; 48(6):1639-46. PubMed ID: 12794832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
    Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
    Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Waszczykowska E; Zalewska A; Sysa-Jedrzejowska A
    Mediators Inflamm; 2005 Aug; 2005(3):144-9. PubMed ID: 16106100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
    Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
    J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small intestinal bacterial overgrowth in systemic sclerosis.
    Marie I; Ducrotté P; Denis P; Menard JF; Levesque H
    Rheumatology (Oxford); 2009 Oct; 48(10):1314-9. PubMed ID: 19696066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.
    Vonk MC; Marjanovic Z; van den Hoogen FH; Zohar S; Schattenberg AV; Fibbe WE; Larghero J; Gluckman E; Preijers FW; van Dijk AP; Bax JJ; Roblot P; van Riel PL; van Laar JM; Farge D
    Ann Rheum Dis; 2008 Jan; 67(1):98-104. PubMed ID: 17526554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.